OR WAIT null SECS
The expansions will add peptide manufacturing capacity.
CordenPharma announced on May 13, 2021 that it plans to expand its non-GMP capacity at its Centre of Excellence for Peptide Process Development in Frankfurt, Germany, and increase its upstream capacity at its CordenPharma Colorado site with the introduction of a new 3000-L solid phase peptide synthesis (SPPS) vessel.
The capacity expansions fall in line with CordenPharma’s strategy to provide its customers with quick and economically appealing solutions, the company said in a press release. In addition to the new SPPS vessel, CordenPharma plans to add a second 100-cm high-pressure chromatography column at its CordenPharma Colorado site.
“This additional column will provide the capacity to purify several tons of peptide annually, which in conjunction with our existing 100 and 80-cm columns, gives us more flexibility and redundancy to maximize supply security for all of our partners,” said Matthieu Giraud, PhD, global director of the Peptides, Lipids & Carbohydrates Platform, CordenPharma, in the press release.